Immunohistochemical Subtype Conversion and Pathological Response After Neoadjuvant Chemotherapy in Luminal B HER2-Negative Locally Advanced Breast Cancer: A Cross-Sectional Study
DOI:
https://doi.org/10.37275/bsm.v10i11.1680Keywords:
Breast neoplasms, Indonesia, Neoadjuvant therapy, Neoplasm, residual, Receptor, ErbB-2Abstract
Background: Luminal B HER2-negative breast cancer responds only modestly to neoadjuvant chemotherapy (NAC), and the receptor profile of its residual tumor may differ from that of the original biopsy.
Objective: To test whether subtype conversion after NAC is associated with pathological response.
Methods: This retrospective cross-sectional study included 49 consecutive women with stage IIIA–IIIB Luminal B HER2-negative cancer who received doxorubicin–cyclophosphamide or docetaxel–cyclophosphamide before mastectomy at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia (2024–2025). Conversion meant any change in immunohistochemical surrogate subtype between core biopsy and mastectomy. The outcomes were the Miller–Payne grade (primary) and the Residual Cancer Burden (RCB) class. Exact tests, proportional-odds and Firth logistic regression, and Holm correction were applied.
Results: Conversion occurred in 14 patients (28.6%; 95% CI 17.8–42.4), most often to Luminal B HER2-positive. Converted tumors had lower Miller–Payne grades (exact p = 0.027). None reached grade 4–5 (0/14 vs 9/35; p = 0.045). The adjusted cumulative odds ratio was 0.27 (95% CI 0.08–0.91). RCB-III was more frequent after conversion (78.6% vs 31.4%; adjusted OR 6.54, 95% CI 1.69–31.63). The association between conversion and the RCB class was the only one surviving Holm correction (p = 0.019), and the RCB-III association depended largely on eight HER2 gains defined by immunohistochemistry alone.
Conclusion: More than one in four Luminal B HER2-negative tumors changed surrogate subtype after NAC. Conversion, mostly HER2 gain, marked heavier residual disease. Before adjuvant therapy is chosen, receptors should be re-tested on residual tumor, with in situ hybridization to confirm HER2.
Authors
- Syifa Azizah Putri1*
- Kiki Akhmad Rizki2
- Bethy Suryawathy Hernowo3
- 1Subspecialist Training Program in Surgical Oncology, Department of Surgery, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
- 2Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
- 3Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
Corresponding author Syifa Azizah Putri — syfsyifaa@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Syifa Azizah Putri, Kiki Akhmad Rizki, Bethy Suryawathy Hernowo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
